Home LiteratureArticle Details
PMID: 12225357 Published · ppublish English Journal Article Review

Regulation of tumour immunity by CD25+ T cells.

Immunology ·Vol. 107 ·No. 1 ·2002-09-00 ·Pages 5-9

Gallimore A, Sakaguchi S

Abstract

暂无摘要

MeSH Terms
Animals Humans Immune Tolerance/immunology Immunity, Cellular Mice Neoplasms/immunology Receptors, Interleukin-2/analysis T-Lymphocyte Subsets/immunology
Chemicals
Receptors, Interleukin-2
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Gallimore Awen
Medical Biochemistry, University of Wales College of Medicine, Cardiff, UK. [email protected]
Sakaguchi Shimon
References (42)
42 references, click to expand
  1. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells.
    Blood. 2001 Nov 1;98(9):2736-44 PMID: 11675346
  2. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.
    J Immunol. 1999 May 1;162(9):5317-26 PMID: 10228007
  3. Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.
    J Exp Med. 2001 Jun 4;193(11):1295-302 PMID: 11390436
  4. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance.
    Nat Immunol. 2002 Feb;3(2):135-42 PMID: 11812990
  5. Regulatory T cells in spontaneous autoimmune encephalomyelitis.
    Immunol Rev. 2001 Aug;182:122-34 PMID: 11722629
  6. T cell defined tumor antigens.
    Curr Opin Immunol. 1997 Oct;9(5):684-93 PMID: 9368778
  7. Differentiation of T regulatory cells by immature dendritic cells.
    J Exp Med. 2001 Jan 15;193(2):F5-9 PMID: 11208869
  8. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation.
    J Exp Med. 2000 Jul 17;192(2):295-302 PMID: 10899916
  9. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells.
    J Immunol. 2001 Aug 1;167(3):1137-40 PMID: 11466326
  10. Thymic selection of CD4+CD25+ regulatory T cells induced by an agonist self-peptide.
    Nat Immunol. 2001 Apr;2(4):301-6 PMID: 11276200
  11. Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro.
    Eur J Immunol. 2001 Apr;31(4):1247-54 PMID: 11298351
  12. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.
    J Exp Med. 1996 Aug 1;184(2):387-96 PMID: 8760792
  13. Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells.
    J Exp Med. 2001 Aug 20;194(4):427-38 PMID: 11514600
  14. Regulatory T cells in autoimmmunity*.
    Annu Rev Immunol. 2000;18:423-49 PMID: 10837065
  15. Peripheral selection of the T cell repertoire.
    Science. 1991 Mar 8;251(4998):1225-8 PMID: 1900951
  16. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
    Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2982-7 PMID: 10077623
  17. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood.
    J Exp Med. 2001 Jun 4;193(11):1285-94 PMID: 11390435
  18. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.
    J Exp Med. 2000 Jul 17;192(2):303-10 PMID: 10899917
  19. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation.
    J Exp Med. 1999 Oct 4;190(7):995-1004 PMID: 10510089
  20. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
    Int Immunol. 1998 Dec;10(12):1969-80 PMID: 9885918
  21. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
    J Exp Med. 1998 Jul 20;188(2):277-86 PMID: 9670040
  22. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    J Immunol. 1999 Nov 15;163(10):5211-8 PMID: 10553041
  23. Regulatory T cells: key controllers of immunologic self-tolerance.
    Cell. 2000 May 26;101(5):455-8 PMID: 10850488
  24. Tolerance, danger, and the extended family.
    Annu Rev Immunol. 1994;12:991-1045 PMID: 8011301
  25. Cancer Tumor antigens.
    Curr Opin Immunol. 1997 Oct 1;9(5):681-3 PMID: 9438857
  26. Immunity against cancer: lessons learned from melanoma.
    Curr Opin Immunol. 2001 Apr;13(2):134-40 PMID: 11228404
  27. Policing the regulators.
    Nat Immunol. 2001 Apr;2(4):283-4 PMID: 11276194
  28. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.
    Immunity. 2000 Apr;12(4):431-40 PMID: 10795741
  29. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood.
    J Exp Med. 2001 Jun 4;193(11):1303-10 PMID: 11390437
  30. Depletion of CD25+ regulatory cells results in suppression of melanoma growth and induction of autoreactivity in mice.
    Cancer Immun. 2002 Feb 22;2:1 PMID: 12747746
  31. An autologous oral DNA vaccine protects against murine melanoma.
    Proc Natl Acad Sci U S A. 2000 May 9;97(10):5492-7 PMID: 10779556
  32. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.
    Cancer Res. 2000 Jan 15;60(2):253-8 PMID: 10667570
  33. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    J Exp Med. 2001 Sep 17;194(6):823-32 PMID: 11560997
  34. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells.
    J Exp Med. 2000 Nov 6;192(9):1213-22 PMID: 11067871
  35. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
    Cancer Res. 1999 Jul 1;59(13):3128-33 PMID: 10397255
  36. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.
    J Exp Med. 1998 Jul 20;188(2):287-96 PMID: 9670041
  37. A critical role for transforming growth factor-beta but not interleukin 4 in the suppression of T helper type 1-mediated colitis by CD45RB(low) CD4+ T cells.
    J Exp Med. 1996 Jun 1;183(6):2669-74 PMID: 8676088
  38. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.
    J Exp Med. 2000 Dec 4;192(11):1637-44 PMID: 11104805
  39. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.
    Nature. 2001 Jun 28;411(6841):1058-64 PMID: 11429607
  40. T cell tolerance by clonal elimination in the thymus.
    Cell. 1987 Apr 24;49(2):273-80 PMID: 3494522
  41. Clonal deletion versus clonal anergy: the role of the thymus in inducing self tolerance.
    Science. 1990 Jun 15;248(4961):1342-8 PMID: 1972593
  42. The makings of a tumor rejection antigen.
    Immunity. 1999 Sep;11(3):263-70 PMID: 10514004
Article Info
Journal
Immunology
Abbr.
Immunology
ISSN
0019-2805
DOI
10.1046/j.1365-2567.2002.01471.x
Email
[email protected]
Published
2002-09-00
Pages
5-9
Language
English
Region
England
NLM ID
0374672
PMCID
PMC1782775
Subset
IM
External Links
PubMed source DOI: 10.1046/j.1365-2567.2002.01471.x PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2